Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients
Panelists discuss how referral types for multiple myeloma patients vary widely, including newly diagnosed cases, relapsed/refractory disease, and specific therapy considerations like bispecifics, with processes differing between in-state and out-of-state referrals due to logistical and insurance factors.
EP: 1.The Power of Partnership: Enhancing Patient Care in Multiple Myeloma through Academic and Community Physician Collaboration
EP: 2.Fast-Tracking Care: Streamlining Referrals for Quicker Treatment in Multiple Myeloma
EP: 3.Collaborative Care vs. Independent Treatment: Does It Impact Patient Outcomes in Multiple Myeloma?
EP: 4.Overcoming Challenges in Patient Referrals: Handling Reluctance and Navigating Barriers to Academic Care
EP: 5.When Is the Right Time? Navigating Key Moments for Referring Multiple Myeloma Patients to an Academic Center
EP: 6.Identifying and Referring Candidates for Bispecific Therapy: Key Factors in Transitioning from Community to Academic Care
EP: 7.Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care
EP: 8.Inside the Academic Approach: How Initial Consultations for Bispecific Therapy Referrals Are Handled
EP: 9.Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies
Now Viewing
EP: 10.Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients
EP: 11.Criteria for Transitioning Patients from Bispecific Therapy to Community Oncologist Care in Multiple Myeloma
EP: 12.Protocols for Monitoring and Managing Long-Term Complications of Bispecific Therapy in Mutlplie Myeloma
EP: 13.Enhancing Communication Between Academic and Community Oncologists During Referral and Treatment in Multiple Myeloma.
EP: 14.Optimizing Patient Reintegration into Community Care Post-Academic Treatment of Bispecifics in Multiple Myeloma
EP: 15.Unmet Needs and Future Directions for Enhancing Bispecific Therapy Care Transitions in Multiple Myeloma
Video content above is prompted by the following:
- What types of referrals do you usually do?
- Is the process similar/different for in-state vs out-state?
- How do social factors play into the referral process?
- How do the AEs differ based on the class of bispecific? Which AEs are you seeing in practice?
- How are they managed?
Related Content
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Article
Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
